SCHEMBL21768460

SCHEMBL21768460

CS(=O)(=O)c1ccncc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 9/20 0.43
CA2 P00918 9/20 0.43
CA9 Q16790 9/20 0.43
CA1 P00915 8/20 0.43
CA14 Q9ULX7 8/20 0.43
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40
BLM P54132 1/20 0.40
CASP7 P55210 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PTGS1 P23219 4/20 0.38
PTGS2 P35354 4/20 0.38
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5700058 0.83 CA12 (0.47) CA12CA2CA9CA1CA14
SCHEMBL31247452 0.83 CA12 (0.47) CA12CA2CA9CA1CA14
SCHEMBL3010471 0.79 CA12 (0.40) CA12CA2CA9CA1CA14
SCHEMBL31173473 0.79 CA12 (0.40) CA12CA2CA9CA1CA14
SCHEMBL2646684 0.77 CA12 (0.39) CA12CA2CA9CA1CA14
SCHEMBL19144940 0.77 L3MBTL1 (0.44) CA12CA2CA9CA1CA14
SCHEMBL23665029 0.75 CA12 (0.38) CA12CA2CA9CA1CA14
SCHEMBL30784405 0.75 PTGS2 (0.42) CA12CA2CA9CA1CA14
SCHEMBL30050575 0.75 KDM4E (0.47) CA12CA2CA9CA1CA14
SCHEMBL2646686 0.75 CA12 (0.42) CA12CA2CA9CA1CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2023-09-28 US disclosed
EP-3722284-A1 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2020-10-14 EP disclosed
EP-3402781-B1 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES GRUENENTHAL GMBH (DE) 2020-03-04 EP disclosed
CN-107001317-B Highly selective substituted uracil PI3K inhibitor 山东轩竹医药科技有限公司 2019-05-24 CN disclosed
CN-107001317-A High selectivity substituted uracil PI3K inhibitor 山东轩竹医药科技有限公司 2017-08-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303573-A1 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, OPRL1 CA12 3971/4885CA2 2068/4885CA9 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.